Daniel Gordon Kirby bought $55k of IOVA
Chief Commercial Officer at IOVANCE BIOTHERAPEUTICS, INC.. 30,000 shares at an average of $1.84, traded Jun 5, 2025, filed Jun 6, 2025.
Score components
- +15RoleOfficer
- +7Trade size$55k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +18Price context8% above the 52-week low; 85% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -14.6%, 3m +21.5%, 6m +7.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-25-057310, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 5, 2025 | POpen-market purchase Common Stock | +30,000 | $1.84 | $55k | 30,000 | Jun 6, 2025 |
Related signals
Other insiders at IOVANCE BIOTHERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 48Moderate | IOVANCE BIOTHERAPEUTICS, INC. | Raj K. Puri Chief Regulatory Officer | $9,743 5,600 shares | +3% | |
| 60Notable | IOVANCE BIOTHERAPEUTICS, INC. | Frederick G Vogt Interim CEO & General Counsel | $42k 25,000 shares | +7% | |
| 38Weak | IOVAsell IOVANCE BIOTHERAPEUTICS, INC. | Ryan D Maynard director | $503k 50,000 shares | -87% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.